SEEGENE, INC. Logo

SEEGENE, INC.

Develops multiplex PCR-based IVD products and automated diagnostic systems.

096530 | KO

Overview

Corporate Details

ISIN(s):
KR7096530001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 오금로 91(방이동) 7층, 서울특별시

Description

Seegene, Inc. is a company specializing in molecular diagnostics. It develops and manufactures in vitro diagnostic (IVD) products and automated systems based on its proprietary multiplex real-time PCR technologies. These technologies enable the simultaneous detection of multiple pathogens from a single sample, facilitating a syndromic testing approach for various conditions. The company's portfolio includes a broad range of diagnostic assays for infectious diseases, including respiratory illnesses, sexually transmitted infections (STIs), and human papillomavirus (HPV). Seegene also provides automated platforms, such as its All-in-One systems, to streamline laboratory workflows. The company engages in technology-sharing initiatives and strategic collaborations to advance the standardization and accessibility of molecular diagnostics globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
자기주식처분결과보고서
Korean 17.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-08 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-08-06 00:00
현금ㆍ현물배당결정 (분기배당)
Korean 8.4 KB
2025-08-06 00:00
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-08-06 00:00
주요사항보고서(자기주식처분결정)
Korean 31.3 KB
2025-08-01 00:00
결산실적공시예고
Korean 4.0 KB
2025-06-11 00:00
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 79.7 KB
2025-06-09 00:00
자기주식처분결과보고서
Korean 17.6 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 2.1 MB
2025-05-09 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-05-07 00:00
현금ㆍ현물배당결정 (분기배당)
Korean 8.4 KB
2025-05-07 00:00
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-05-07 00:00
주요사항보고서(자기주식처분결정)
Korean 31.4 KB
2025-05-02 00:00
결산실적공시예고
Korean 4.0 KB

Automate Your Workflow. Get a real-time feed of all SEEGENE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEEGENE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEEGENE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.